Eplontersen is a novel ligand-coupled antisense oligonucleotide drug for the treatment of transthyretin amyloid polyneuropathy (ATTR-PN). Compared with inotersen, eplontersen has a lower dosage and a lower frequency of administration, while its safety is improved. This article reviewed the mechanism, clinical efficacy and safety of eplontersen in the treatment of ATTR-PN, aiming to provide a reference for clinical medication.